Nurses working in this area of health have reviewed the Appraisal Consultation Document of the technology appraisal of Bevacizumab for the treatment of recurrent advanced ovarian cancer [ID490].

There are no further comments to submit at this stage on behalf of the Royal College of Nursing.

Thank you for the opportunity to review the document.

We look forward to participating in the next stage of the appraisal.

Please acknowledge receipt.